Cargando…
Disposition and metabolism of [(14)C]-levomilnacipran, a serotonin and norepinephrine reuptake inhibitor, in humans, monkeys, and rats
Levomilnacipran is approved in the US for the treatment of major depressive disorder in adults. We characterized the metabolic profile of levomilnacipran in humans, monkeys, and rats after oral administration of [(14)C]-levomilnacipran. In vitro binding of levomilnacipran to human plasma proteins wa...
Autores principales: | Brunner, Valérie, Maynadier, Bernadette, Chen, Laishun, Roques, Louise, Hude, Isabelle, Séguier, Sébastien, Barthe, Laurence, Hermann, Philippe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484650/ https://www.ncbi.nlm.nih.gov/pubmed/26150694 http://dx.doi.org/10.2147/DDDT.S80886 |
Ejemplares similares
-
Sentiment Analysis of Online Reviews for Selective Serotonin Reuptake Inhibitors and Serotonin–Norepinephrine Reuptake Inhibitors
por: Compagner, Chad, et al.
Publicado: (2021) -
Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans
por: Chen, Laishun, et al.
Publicado: (2015) -
Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors
por: Briley, Mike, et al.
Publicado: (2010) -
Serotonin-Norepinephrine Reuptake Inhibitors for Pain Control: Premise and Promise
por: Marks, David M, et al.
Publicado: (2009) -
Selective Serotonin–norepinephrine Reuptake Inhibitors-induced Takotsubo Cardiomyopathy
por: Vasudev, Rahul, et al.
Publicado: (2016)